Literature DB >> 8284689

Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.

M A Caligiuri1.   

Abstract

Interleukin-2 is a lymphocytotrophic hormone that plays a critical role in the host's normal immune response. Deficiencies in the production of IL-2 are likely to be important in the pathogenesis of certain infectious and malignant diseases. A better understanding of IL-2 and its potential applications in the treatment of human disease will come about with continued efforts in at least two areas. First, we must continue to characterize IL-2 receptor expression on the cells that normally use IL-2, in an attempt to fully elucidate their functional responsiveness to this hormone in vitro and their physiologic role in vivo. Second, we should proceed with clinical trials that use rIL-2 in an effort to assess cellular and humoral responses in vivo, and to learn more about the ability of rIL-2 to provide additional defense against persistent infection or malignancy in both immunocompromised and cancer patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8284689

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

1.  Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25.

Authors:  Megan C Duggan; Amanda R Campbell; Elizabeth L McMichael; Kallan S Opheim; Kala M Levine; Neela Bhave; Michelle C Culbertson; Tiffany Noel; Lianbo Yu; W E Carson
Journal:  Oncoimmunology       Date:  2017-10-16       Impact factor: 8.110

Review 2.  A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection.

Authors:  S C Piscitelli; N Bhat; A Pau
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

3.  Long-term complete response to very-low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma: report of two cases.

Authors:  Ken-Ichi Harada; Hideaki Miyake; Toshifumi Kurahashi; Masato Fujisawa
Journal:  Clin Exp Nephrol       Date:  2011-08-17       Impact factor: 2.801

4.  Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

Authors:  V P Khatri; T A Fehniger; R A Baiocchi; F Yu; M H Shah; D S Schiller; M Gould; R T Gazzinelli; Z P Bernstein; M A Caligiuri
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

5.  Effectiveness of very low doses of immunotherapy in advanced renal cell cancer.

Authors:  C Buzio; G De Palma; R Passalacqua; D Potenzoni; F Ferrozzi; M A Cattabiani; L Manenti; A Borghetti
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.

Authors:  E L Jacobson; F Pilaro; K A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

7.  In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.

Authors:  P Lissoni; L Fumagalli; F Rovelli; F Brivio; G Di Felice; F Majorca
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.